Vensana Capital, a med-tech focused investment firm, announced Tuesday it raised a second fund worth $325 million.
The Minneapolis and Washington, D.C.-based firm invests in med-tech companies in their development and commercial stages.
Since closing its first fund of $225 million in Sept. 2019, Vensana has made 10 investments, including Wayne, Pennsylvania-based Intact Vascular, which was acquired by Phillips, and Minneapolis-based CVRx, which completed an IPO in June.
The firm recently hired Venture Partner Mike Kramer and Principal Amrinder Singh, along with Chief Financial Officer Steve Schwen. Kramer joins from healthcare investment firm CRG, while Singh moved from Medtronic Ventures.
“We are proud of the progress that Vensana has made since launch – especially our growing investment team and our portfolio of companies tackling important unmet needs – and we are grateful for the continued strong support of our limited partners,” said Managing Partner Kirk Nielsen. “Our entire team is excited about the opportunity in front of us as we work hard to build a leading medtech investment and company building platform.”
